ADAPT technique with ACE68 and ACE64 reperfusion catheters in ischemic stroke treatment : Results from the PROMISE study
This study was funded by Penumbra, inc (9508). ; Competing interests The following investigators report financial conflicts with this study: Ps reports being a consultant for Penumbra and stryker, and receiving research support from Penumbra, Philips, and siemens. rP reports proctoring and consulting for Medtronic, Penumbra, and implemed. WW reports a proctor agreement with Microvention/Terumo, Medtronic, and Phenox, and being a consultant with Penumbra (speaker and chairman fees). JF reports being a consultant for Penumbra, acandis, Boehringer ingelheim, cerenovus, covidien, Medtronic, Microvention, route92, and stryker, and receiving research support from the german Ministry of science and education (BMBF), german Ministry of economy and innovation (BMWi), german research Foundation (DFg), european Union (eU), hamburgische investitions-und Förderbank (iFB), Medtronic, Microvention, Philips, and stryker. PM reports speaker and consulting fees from Medtronic, used for stroke education. TK and VMP received funding from the sponsor for imaging core lab oratory activities. VMP reports being a consultant for Penumbra (PrOMise study), Medtronic, stryker, and neurovasc. lP received funding from Penumbra for cec activities and is a consultant for Balt, cerenovus/neuravi, and Microvention. ; Background and purpose The recent randomized trials demonstrated the benefit of mechanical thrombectomy in stroke therapy. However, treatment using different strategies is an ongoing area of investigation. The PROMISE study analyzed the safety and effectiveness of the Penumbra System with the ACE68 and ACE64 reperfusion catheters in aspiration thrombectomy of stroke, using A Direct Aspiration First Pass Technique (ADAPT). Methods PROMISE was a prospective study which enrolled 204 patients with intracranial anterior circulation large vessel occlusion (LVO) ischemic stroke in 20 centers from February 2016 to May 2017. Initial treatment was with the ACE68/ACE64 catheters within 6 hours of symptom onset. Imaging and safety review was ...
